List of Alexion Pharmaceuticals patents

Patents where

Current Assignee

Name

Alexion Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11802154 Humanized anti-CD200 antibodies and uses thereof	Patent 11802154 was granted and assigned to Alexion Pharmaceuticals on October, 2023 by the United States Patent and Trademark Office.	Alexion Pharmaceuticals	Alexion Pharmaceuticals	United States Patent and Trademark Office	11802154	October 31, 2023
‌ US Patent 6982323 Chimeric proteins for diagnosis and treatment of diabetes	Patent 6982323 was granted and assigned to Alexion Pharmaceuticals on January, 2006 by the United States Patent and Trademark Office.		Alexion Pharmaceuticals	United States Patent and Trademark Office	6982323	January 3, 2006
‌ US Patent 9658236 Atypical hemolytic uremic syndrome (aHUS) biomarker proteins	Patent 9658236 was granted and assigned to Alexion Pharmaceuticals on May, 2017 by the United States Patent and Trademark Office.	Alexion Pharmaceuticals	Alexion Pharmaceuticals	United States Patent and Trademark Office	9658236	May 23, 2017
‌ US Patent 10590189 Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement	Patent 10590189 was granted and assigned to Alexion Pharmaceuticals on March, 2020 by the United States Patent and Trademark Office.	Alexion Pharmaceuticals	Alexion Pharmaceuticals	United States Patent and Trademark Office	10590189	March 17, 2020
‌ US Patent 9732149 Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement	Patent 9732149 was granted and assigned to Alexion Pharmaceuticals on August, 2017 by the United States Patent and Trademark Office.	Alexion Pharmaceuticals	Alexion Pharmaceuticals	United States Patent and Trademark Office	9732149	August 15, 2017
‌ US Patent 9725504 Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement	Patent 9725504 was granted and assigned to Alexion Pharmaceuticals on August, 2017 by the United States Patent and Trademark Office.	Alexion Pharmaceuticals	Alexion Pharmaceuticals	United States Patent and Trademark Office	9725504	August 8, 2017
‌ US Patent 10000532 Bone delivery conjugates and method of using same to target proteins to bone	Patent 10000532 was granted and assigned to Alexion Pharmaceuticals on June, 2018 by the United States Patent and Trademark Office.		Alexion Pharmaceuticals	United States Patent and Trademark Office	10000532	June 19, 2018
‌ US Patent 9494601 Atypical hemolytic uremic syndrome (AHUS) biomarker proteins	Patent 9494601 was granted and assigned to Alexion Pharmaceuticals on November, 2016 by the United States Patent and Trademark Office.		Alexion Pharmaceuticals	United States Patent and Trademark Office	9494601	November 15, 2016
‌ US Patent 9718880 Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement	Patent 9718880 was granted and assigned to Alexion Pharmaceuticals on August, 2017 by the United States Patent and Trademark Office.	Alexion Pharmaceuticals	Alexion Pharmaceuticals	United States Patent and Trademark Office	9718880	August 1, 2017
‌ US Patent 11560554 Lysosomal storage disease enzymes		Alexion Pharmaceuticals	Alexion Pharmaceuticals	United States Patent and Trademark Office	11560554	January 24, 2023
‌ US Patent 11352612 Manufacturing of alkaline phosphatases		Alexion Pharmaceuticals	Alexion Pharmaceuticals	United States Patent and Trademark Office	11352612	June 7, 2022
‌ US Patent 9771418 Methods for treating complement-associated disorders	Patent 9771418 was granted and assigned to Alexion Pharmaceuticals on September, 2017 by the United States Patent and Trademark Office.	Alexion Pharmaceuticals	Alexion Pharmaceuticals	United States Patent and Trademark Office	9771418	September 26, 2017
‌ US Patent 9447176 Methods and compositions for treating complement-associated disorders	Patent 9447176 was granted and assigned to Alexion Pharmaceuticals on September, 2016 by the United States Patent and Trademark Office.		Alexion Pharmaceuticals	United States Patent and Trademark Office	9447176	September 20, 2016
‌ US Patent 9579366 Recombinant human NaGlu protein and uses thereof	Patent 9579366 was granted and assigned to Alexion Pharmaceuticals on February, 2017 by the United States Patent and Trademark Office.	Synageva BioPharma	Alexion Pharmaceuticals	United States Patent and Trademark Office	9579366	February 28, 2017
‌ US Patent 9988620 Methods, compositions, and kits for the treatment of matrix mineralization disorders	Patent 9988620 was granted and assigned to Alexion Pharmaceuticals on June, 2018 by the United States Patent and Trademark Office.		Alexion Pharmaceuticals	United States Patent and Trademark Office	9988620	June 5, 2018
‌ US Patent 10493135 Methods of treating tissue calcification	Patent 10493135 was granted and assigned to Alexion Pharmaceuticals on December, 2019 by the United States Patent and Trademark Office.	Alexion Pharmaceuticals	Alexion Pharmaceuticals	United States Patent and Trademark Office	10493135	December 3, 2019
‌ US Patent 9447187 Use of an anti-CD200 antibody for prolonging the survival of allografts	Patent 9447187 was granted and assigned to Alexion Pharmaceuticals on September, 2016 by the United States Patent and Trademark Office.		Alexion Pharmaceuticals	United States Patent and Trademark Office	9447187	September 20, 2016
‌ US Patent 9415102 High concentration formulations of anti-C5 antibodies	Patent 9415102 was granted and assigned to Alexion Pharmaceuticals on August, 2016 by the United States Patent and Trademark Office.		Alexion Pharmaceuticals	United States Patent and Trademark Office	9415102	August 16, 2016
‌ US Patent 9862767 Therapeutic methods using anti-CD200 antibodies	Patent 9862767 was granted and assigned to Alexion Pharmaceuticals on January, 2018 by the United States Patent and Trademark Office.		Alexion Pharmaceuticals	United States Patent and Trademark Office	9862767	January 9, 2018
‌ US Patent 9556263 Methods for treating atypical hemolytic uremic syndrome with high concentration formulations of anti-C5 antibodies	Patent 9556263 was granted and assigned to Alexion Pharmaceuticals on January, 2017 by the United States Patent and Trademark Office.	Alexion Pharmaceuticals	Alexion Pharmaceuticals	United States Patent and Trademark Office	9556263	January 31, 2017
‌ US Patent 9352035 High concentration antibody formulations	Patent 9352035 was granted and assigned to Alexion Pharmaceuticals on May, 2016 by the United States Patent and Trademark Office.		Alexion Pharmaceuticals	United States Patent and Trademark Office	9352035	May 31, 2016
‌ US Patent 8114403 Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof	Patent 8114403 was granted and assigned to Alexion Pharmaceuticals on February, 2012 by the United States Patent and Trademark Office.		Alexion Pharmaceuticals	United States Patent and Trademark Office	8114403	February 14, 2012
‌ US Patent 11365241 High concentration anti-C5 antibody formulations	Patent 11365241 was granted and assigned to Alexion Pharmaceuticals on June, 2022 by the United States Patent and Trademark Office.	Alexion Pharmaceuticals	Alexion Pharmaceuticals	United States Patent and Trademark Office	11365241	June 21, 2022
‌ US Patent 10584164 Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodies	Patent 10584164 was granted and assigned to Alexion Pharmaceuticals on March, 2020 by the United States Patent and Trademark Office.	Alexion Pharmaceuticals	Alexion Pharmaceuticals	United States Patent and Trademark Office	10584164	March 10, 2020
‌ US Patent 9663574 Anti-C5 antibodies having improved pharmacokinetics	Patent 9663574 was granted and assigned to Alexion Pharmaceuticals on May, 2017 by the United States Patent and Trademark Office.	Alexion Pharmaceuticals	Alexion Pharmaceuticals	United States Patent and Trademark Office	9663574	May 30, 2017

...

Results per page:

107 results

0 selected

107 results

0 selected